UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16

UNDER THE SECURITIES EXCHANGE ACT of 1934

 

For the month of May 2016

 

001-37521

(Commission File Number)

 

INTEC PHARMA LTD.

(Translation of registrant’s name into English)

 

12 Hartom Street
Har Hotzvim, Jerusalem 9777512, Israel

(+972) (2) 586-4657

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover

Form 20-F or Form 40-F.

 

Form 20-F ☒ Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(l): _________

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): _________

 

 

 
 

 

Attached hereto as Exhibit 99.1, and incorporated by way of reference, is a convenience translation into English of a notice published by the company on May 24, 2016, in two daily Israeli newspapers and entitled “Notice of Annual General Meeting of Shareholders” (the “Notice”). The attached Notice was published pursuant to the requirements of the Israeli law, and the original version of the notice is in Hebrew. The foregoing document is attached for information purposes only and does not constitute a proxy solicitation on behalf of the company. The company's proxy solicitation materials for distribution in the United States will be furnished separately on or about June 6, 2016.

 

 


 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

  INTEC PHARMA LTD.
   
  By:  /s/ Zeev Weiss
    Name: Zeev Weiss
Title: Chief Executive Officer

 

Date: May 24, 2016

 

 

 
 

 

EXHIBIT INDEX

Exhibit No. Description  
     
99.1 Convenience Translation from Hebrew of Notice of Annual General Meeting of Shareholders, dated May 24, 2016.
     
     

 

Exhibit 99.1

Intec Pharma Ltd.

Company No. 51-302278-0

Hartom 12 St., Jerusalem 9777512

 

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

Notice is hereby given that the annual general meeting of shareholders of Intec Pharma Ltd. (the “Company”), will be held at the offices of Gross, Kleinhendler, Hodak, Halevy, Greenberg & Co., One Azrieli Center, Round Building, Tel Aviv 6701101, Israel on Thursday, June 30, 2016, at 04:00 p.m. Israel time (the telephone number at that address is +972-3-607-4444), or at any adjournments thereof (the “Meeting”).

 

The agenda of the Meeting shall be as follows:

1.To elect Mr. John W. Kozarich, and re-elect each of Messrs., Zeev Weiss, Amir Hayek, Giora Carni, Zvika Joseph and Ms. Hila Karah as director of the Company to hold office until the close of the next annual general meeting;
2.To approve the compensation terms of the chairman of the Company’s board of directors, Mr. John W. Kozarich, subject to his election as a director at the Meeting;
3.To approve the grant of options to Mr. Giora Carni, Company’s Director of Technology, subject to his re-election as a director at the Meeting;
4.To approve the compensation terms of Mr. Zvika Joseph, as Manager of the Company’s Investor Relations activities in Israel, subject to his re-election as a director at the Meeting;
5.To approve the grant of options to directors of the Company (other than external directors, the Chairman of the Company's board of directors and any director that serves as an officer); and
6.To approve and ratify the re-appointment of Kesselman & Kesselman as the independent auditors of the Company for the period ending at the close of the next annual general meeting.

In addition, the shareholders will be requested to consider at the Meeting the Company’s audited financial statements for the years ended December 31, 2014 and December 31, 2015.

Only holders of record at the close of business on Tuesday, May 31, 2016 are entitled to receive notice of, and to vote at, the Meeting.

Position Statements should be submitted to the Company no later than Monday, June 20, 2016.

A duly executed proxy must be received no later than Thursday, June 30, 2016, at 12:00 p.m., Israel time.

The report with respect to convening the meeting will be available to the public through the Magna website at http://www.magna.isa.gov.il.

 

    Intec Pharma Ltd.